1
|
Thaci D, Piaserico S, Warren RB, Gupta AK, Cantrell W, Draelos Z, Foley P, Igarashi A, Langley RG, Asahina A, Young M, Falqués M, Pau-Charles I, Mendelsohn AM, Rozzo SJ, Reich K. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). Br J Dermatol 2021; 185:323-334. [PMID: 33544883 DOI: 10.1111/bjd.19866] [Citation(s) in RCA: 45] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/04/2021] [Indexed: 12/30/2022]
Abstract
BACKGROUND The phase III reSURFACE 1 and reSURFACE 2 (NCT01722331/NCT01729754) trials of the anti-interleukin-23p19 monoclonal antibody tildrakizumab (TIL) for psoriasis treatment are complete. OBJECTIVES We present 5-year pooled data from reSURFACE 1 and reSURFACE 2. METHODS reSURFACE 1 and reSURFACE 2 were double-blind, randomized, controlled studies with optional long-term extensions. Adults with moderate-to-severe chronic plaque psoriasis were randomized 2 : 2 : 1 to TIL 100 mg (TIL 100) or 200 mg (TIL 200) or placebo at weeks 0 and 4, and every 12 weeks thereafter [reSURFACE 2 included an etanercept (ETN) arm]. Efficacy outcomes included proportions of patients achieving absolute and relative improvement from baseline Psoriasis Area and Severity Index (PASI) score through week 244 in TIL responders (≥ 75% improvement from baseline PASI; PASI 75 response) continuously receiving the same dose and ETN partial responders and nonresponders (PASI < 75 response) switched to TIL 200 at week 28. Safety was assessed from adverse events (AEs) in all patients as treated. RESULTS Efficacy analyses included 329 and 227 week 28 responders to TIL 100 and TIL 200, respectively, and 121 ETN partial responders/nonresponders switched to TIL 200 at week 28. Of TIL 100 or TIL 200 responders and ETN partial responders/nonresponders entering the extensions, 235/302, 176/213 and 85/107, respectively, were evaluated at week 244, and 88·7%, 92·5% and 81·3%, respectively, achieved PASI 75 response. Exposure-adjusted rates of serious AEs were 6·3 and 6·0 patients with events per 100 patient-years of TIL 100 and TIL 200, respectively. CONCLUSIONS TIL treatment provided sustained disease control over 5 years in week 28 TIL responders and ETN partial responders/nonresponders, with a reassuring safety profile.
Collapse
Affiliation(s)
- D Thaci
- Institute and Comprehensive Centre for Inflammation Medicine, University of Lübeck, Ratzeburger Allee 160, Lübeck, 23538, Germany
| | - S Piaserico
- Dermatology Unit, Department of Medicine, University of Padua, Via Vincenzo Gallucci 4, Padua, 35128, Italy
| | - R B Warren
- The Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, Manchester, M6 8HD, UK
| | - A K Gupta
- Division of Dermatology, Department of Medicine, University of Toronto School of Medicine, 190 Elizabeth Street, R. Fraser Elliott Building, 3-805, Toronto, ON, M5G 2C4, Canada.,Mediprobe Research Inc, 645 Windermere Road, London, ON, N5X 2P1, Canada
| | - W Cantrell
- Village Dermatology, 2900 Cahaba Road, Birmingham, AL, 35223, USA
| | - Z Draelos
- Dermatology Consulting Services, 2444 North Main Street, High Point, NC, 27262, USA
| | - P Foley
- Skin Health Institute Inc., Level 1, 80 Drummond Street, Carlton, Victoria, 3053, Australia
| | - A Igarashi
- NTT Medical Center Tokyo, 5-9-22 Higashi-Gotanda, Shinagawa-ku, Tokyo, 141-8625, Japan
| | - R G Langley
- Division of Dermatology, Department of Medicine, Dalhousie University, 6054 Coburg Road, Halifax, NS, B3H 1Z2, Canada
| | - A Asahina
- Department of Dermatology, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, Tokyo, 105-8461, Japan
| | - M Young
- Mindful Dermatology, Modern Research Associates, 9101 N Central Expy Ste 160, Dallas, TX, 75231, USA
| | - M Falqués
- Almirall R&D, Carrer de Laureà Miró, 408, 410, Sant Feliu de Llobregat, Barcelona, 08980, Spain
| | - I Pau-Charles
- Almirall R&D, Carrer de Laureà Miró, 408, 410, Sant Feliu de Llobregat, Barcelona, 08980, Spain
| | - A M Mendelsohn
- Sun Pharmaceutical Industries, Inc., 2 Independence Way, Princeton, NJ, 08540, USA
| | - S J Rozzo
- Sun Pharmaceutical Industries, Inc., 2 Independence Way, Princeton, NJ, 08540, USA
| | - K Reich
- Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, M, Hamburg, 20246, Germany
| |
Collapse
|
2
|
Cantrell W, Lee P, Mendelsohn AM, Rozzo SJ, Liao W. Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1. J Eur Acad Dermatol Venereol 2021; 35:e526-e528. [PMID: 33460505 PMCID: PMC8359438 DOI: 10.1111/jdv.17124] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- W Cantrell
- Village Dermatology, Birmingham, AL, USA
| | - P Lee
- Center for Clinical Studies, Webster, TX, USA
| | | | - S J Rozzo
- Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA
| | - W Liao
- Department of Dermatology, University of California San Francisco, San Francisco, CA, USA
| |
Collapse
|
3
|
Reich K, Warren R, Iversen L, Puig L, Pau‐Charles I, Igarashi A, Ohtsuki M, Falqués M, Harmut M, Rozzo S, Lebwohl M, Cantrell W, Blauvelt A, Thaçi D. 一项在银屑病患者中开展的 tildrakizumab 药物研究. Br J Dermatol 2020. [DOI: 10.1111/bjd.18844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
4
|
Reich K, Warren R, Iversen L, Puig L, Pau‐Charles I, Igarashi A, Ohtsuki M, Falqués M, Harmut M, Rozzo S, Lebwohl M, Cantrell W, Blauvelt A, Thaçi D. A study of the drug tildrakizumab in psoriasis patients. Br J Dermatol 2020. [DOI: 10.1111/bjd.18831] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
5
|
Reich K, Warren RB, Iversen L, Puig L, Pau-Charles I, Igarashi A, Ohtsuki M, Falqués M, Harmut M, Rozzo S, Lebwohl MG, Cantrell W, Blauvelt A, Thaçi D. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol 2019; 182:605-617. [PMID: 31218661 PMCID: PMC7064936 DOI: 10.1111/bjd.18232] [Citation(s) in RCA: 91] [Impact Index Per Article: 18.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/17/2019] [Indexed: 12/13/2022]
Abstract
Background Tildrakizumab is a specific anti‐interleukin‐23p19 monoclonal antibody approved for the treatment of plaque psoriasis. Objectives To evaluate the long‐term efficacy and safety of tildrakizumab treatment for patients with moderate‐to‐severe psoriasis for up to 148 weeks. Methods Pooled analysis from two double‐blind, randomized controlled trials: reSURFACE 1 and reSURFACE 2. Efficacy was assessed for responders (≥ 75% improvement in Psoriasis Area and Severity Index; PASI 75) and partial responders (PASI 50–75) to tildrakizumab 100 mg and 200 mg at week 28 who were maintained on the same dose (administered every 12 weeks), and for partial responders or nonresponders (PASI < 50) to etanercept 50 mg at week 28 who, after a 4‐week washout, were switched to tildrakizumab 200 mg (administered at weeks 32 and 36, and every 12 weeks thereafter). Safety was assessed in the all‐patients‐as‐treated population. Three different methods of imputing missing data were used: nonresponder imputation (NRI), multiple imputation and observed cases. The Clinicaltrials.gov numbers are NCT01722331 (reSURFACE 1) and NCT01729754 (reSURFACE 2). Results At week 148 (NRI), 72·6%, 53·8% and 28·9% of tildrakizumab 100‐mg responders and 80·2%, 59·9% and 32·6% of tildrakizumab 200‐mg responders had PASI 75, 90 and 100 responses, respectively. For partial responders to tildrakizumab 100 mg and 200 mg, the proportions of patients achieving PASI 75, 90 and 100 responses were 32·5%, 25·0% and 10·0%; and 47·1%, 27·5% and 12·8%, respectively. For patients who were partial responders or nonresponders to etanercept, the proportions of patients achieving PASI 75, 90 and 100 responses were 66·9%, 43·8% and 14·9% at week 148. Rates of discontinuations due to adverse events [tildrakizumab 100 mg: 1·7 per 100 patient‐years (PYs); tildrakizumab 200 mg: 1·2 per 100 PYs] and exposure‐adjusted rates of serious adverse events (5·9 per 100 PYs; 5·5 per 100 PYs), severe infections (1·1 per 100 PYs; 1·1 per 100 PYs), malignancies (0·6 per 100 PYs; 0·4 per 100 PYs) and major adverse cardiovascular events (0·4 per 100 PYs; 0·5 per 100 PYs) were low. Conclusions Tildrakizumab was well tolerated and efficacy was well maintained in week 28 responders who continued tildrakizumab treatment through 3 years, or improved among etanercept partial responders or nonresponders who switched to tildrakizumab. What's already known about this topic? Tildrakizumab 100 mg and 200 mg are efficacious and well tolerated with short‐term use in the treatment of patients with moderate‐to‐severe plaque psoriasis.
What does this study add? High levels of efficacy are maintained for up to 3 years of psoriasis treatment with tildrakizumab. There is a favourable long‐term safety profile with both tildrakizumab 100 mg and 200 mg, with a low incidence of adverse events of special interest through 3 years.
https://doi.org/10.1111/bjd.18831 available online https://www.bjdonline.com/article/
Collapse
Affiliation(s)
- K Reich
- Centre for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Skinflammation® Center, Hamburg, Germany.,Dermatologikum Berlin, Berlin, Germany
| | - R B Warren
- Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, Manchester, U.K
| | - L Iversen
- Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark
| | - L Puig
- Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
| | | | | | - M Ohtsuki
- Department of Dermatology, Jichi Medical University, Tochigi, Japan
| | | | | | - S Rozzo
- Sun Pharmaceuticals, Princeton, NJ, U.S.A
| | - M G Lebwohl
- Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A
| | - W Cantrell
- Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, U.S.A
| | - A Blauvelt
- Oregon Medical Research Center, Portland, OR, U.S.A
| | - D Thaçi
- Institute and Comprehensive Centre for Inflammation Medicine, University of Lübeck, Lübeck, Germany
| |
Collapse
|
6
|
Chandrakar KK, Cantrell W, Shaw RA. Influence of Turbulent Fluctuations on Cloud Droplet Size Dispersion and Aerosol Indirect Effects. J Atmos Sci 2018; 75:3191-3209. [PMID: 30631213 PMCID: PMC6322217 DOI: 10.1175/jas-d-18-0006.1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
Cloud droplet relative dispersion, defined as the standard deviation over the mean cloud droplet size, is of central importance in determining and understanding aerosol indirect effects. In recent work, it was found that cloud droplet size distributions become broader as a result of supersaturation variability and that the sensitivity of this effect is inversely related to cloud droplet number density. The subject is investigated in further detail using an extensive dataset from a laboratory cloud chamber capable of producing steady-state turbulence. An extended stochastic theory is found to successfully describe properties of the droplet size distribution, including an analytical expression for the relative dispersion. The latter is found to depend on the cloud droplet removal time, which in turn increases with the cloud droplet number density. The results show that relative dispersion decreases monotonically with increasing droplet number density, consistent with some recent atmospheric observations. Experiments spanning fast to slow microphysics regimes are reported. The observed dispersion is used to estimate time scales for autoconversion, demonstrating the important role of the turbulence-induced broadening effect on precipitation development. An initial effort is made to extend the stochastic theory to an atmospheric context with a steady updraft, for which autoconversion time is the controlling factor for droplet lifetime. As in the cloud chamber, relative dispersion is found to increase with decreasing cloud droplet number density.
Collapse
Affiliation(s)
- K K Chandrakar
- Atmospheric Sciences Program, and Department of Physics, Michigan Technological University, Houghton, Michigan
| | - W Cantrell
- Atmospheric Sciences Program, and Department of Physics, Michigan Technological University, Houghton, Michigan
| | - R A Shaw
- Atmospheric Sciences Program, and Department of Physics, Michigan Technological University, Houghton, Michigan
| |
Collapse
|
7
|
Chandrakar KK, Cantrell W, Kostinski AB, Shaw RA. Dispersion Aerosol Indirect Effect in Turbulent Clouds: Laboratory Measurements of Effective Radius. Geophys Res Lett 2018; 45:10738-10745. [PMID: 30778268 PMCID: PMC6376200 DOI: 10.1029/2018gl079194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
Cloud optical properties are determined not only by the number density n d and mean radius r ¯ of cloud droplets but also by the shape of the droplet size distribution. The change in cloud optical depth with changing n d , due to the change in distribution shape, is known as the dispersion effect. Droplet relative dispersion is defined as d = σ r / r ¯ . For the first time, a commonly used effective radius parameterization is tested in a controlled laboratory environment by creating a turbulent cloud. Stochastic condensation growth suggests d independent of n d for a nonprecipitating cloud, hence nearly zero albedo susceptibility due to the dispersion effect. However, for size-dependent removal, such as in a laboratory cloud or highly clean atmospheric conditions, stochastic condensation produces a weak dispersion effect. The albedo susceptibility due to turbulence broadening has the same sign as the Twomey effect and augments it by order 10%.
Collapse
Affiliation(s)
- K. K. Chandrakar
- Atmospheric Sciences Program and Department of Physics, Michigan Technological University, Houghton, MI, USA
| | - W. Cantrell
- Atmospheric Sciences Program and Department of Physics, Michigan Technological University, Houghton, MI, USA
| | - A. B. Kostinski
- Atmospheric Sciences Program and Department of Physics, Michigan Technological University, Houghton, MI, USA
| | - R. A. Shaw
- Atmospheric Sciences Program and Department of Physics, Michigan Technological University, Houghton, MI, USA
| |
Collapse
|
8
|
Oak A, Shafi R, Katiyar S, Slominski A, Cantrell W, Wang C, Srivastava R, Li C, Athar M, Elmets C. 289 Oral administration of table grapes has a photoprotective effect on the sunburn response and on cyclobutane pyrimidine dimers in humans in vivo. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.02.319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
9
|
|
10
|
Cantrell W. Inhalation of AEther in Spasmodic Asthma. Prov Med Surg J 2011; 11:278. [PMID: 20794218 DOI: 10.1136/bmj.s1-11.10.278-a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
11
|
Kennedy Carney C, Cantrell W, Elewski BE. Rosacea: a review of current topical, systemic and light-based therapies. GIORN ITAL DERMAT V 2009; 144:673-688. [PMID: 19907406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Rosacea is a common chronic inflammatory disorder of the facial skin characterized by periods of exacerbation, remission and possible progression. The principle subtypes include erythematotelangiectatic rosacea, papulopustular rosacea, phymatous rosacea and ocular rosacea. Although the pathogenesis is unknown, rosacea is largely recognized as an inflammatory disorder. Individual subtypes are likely a result of different pathogenic factors and respond best to different therapeutic regimens. The non-pharmacologic approach to therapy is adequate skin care, trigger avoidance and photoprotection; in addition, there are several topical, herbal, systemic and light based therapies available. Standard Food and Drug Administration (FDA) approved treatments include topical sodium sulfacetamide, metronidazole, and azelaic acid. Anti-inflammatory dose doxycycline, a controlled-release 40 mg formulation offers a non-antibiotic, anti-inflammatory treatment option. Combination of azelaic acid or topical metronidazole with anti-inflammatory doxycycline appears to have a synergistic effect. Oral isotretinoin may be effective for phymatous rosacea and treatment resistant rosacea. Light based therapies with pulsed dye laser and intense pulsed light are effective in treatment of erythema and telangiectasias. As our knowledge of rosacea and its therapeutic options expand, a multifaceted approach to treatment is warranted.
Collapse
Affiliation(s)
- C Kennedy Carney
- Department of Dermatology, University of Alabama at Birmingham, Birmingham AL, USA
| | | | | |
Collapse
|
12
|
|
13
|
Marks S, Varma R, Cantrell W, Chen SC, Gold M, Muellenhoff M, Elewski B. Diclofenac sodium 3% gel as a potential treatment for disseminated superficial actinic porokeratosis. J Eur Acad Dermatol Venereol 2009; 23:42-5. [DOI: 10.1111/j.1468-3083.2008.02943.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
14
|
Varma R, Cantrell W, Elmets C, Elewski B. Infliximab for the treatment of severe pustular psoriasis: 6 years later. J Eur Acad Dermatol Venereol 2008; 22:1253-4. [DOI: 10.1111/j.1468-3083.2008.02596.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
15
|
Abstract
Sarcoidosis is a chronic granulomatous disease of unknown aetiology in which the primary cytokine tumour necrosis factor (TNF)-alpha appears to play a major role. Older immune-modulating drugs including corticosteroids, antimalarials and thalidomide, as well as cytotoxic drugs with immune modulatory effects, have been used to control disease. We present a patient with severe mutilating cutaneous sarcoidosis (lupus pernio) who had showed only partial response to courses of a wide spectrum of immune modulators and cytotoxic therapies, and who had developed significant side-effects due to prolonged high-dose corticosteroids. However, the patient's cutaneous disease responded rapidly to the TNF-alpha inhibitor infliximab.
Collapse
Affiliation(s)
- H Haley
- Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, U.S.A
| | | | | |
Collapse
|
16
|
Ramanathan V, Crutzen PJ, Lelieveld J, Mitra AP, Althausen D, Anderson J, Andreae MO, Cantrell W, Cass GR, Chung CE, Clarke AD, Coakley JA, Collins WD, Conant WC, Dulac F, Heintzenberg J, Heymsfield AJ, Holben B, Howell S, Hudson J, Jayaraman A, Kiehl JT, Krishnamurti TN, Lubin D, McFarquhar G, Novakov T, Ogren JA, Podgorny IA, Prather K, Priestley K, Prospero JM, Quinn PK, Rajeev K, Rasch P, Rupert S, Sadourny R, Satheesh SK, Shaw GE, Sheridan P, Valero FPJ. Indian Ocean Experiment: An integrated analysis of the climate forcing and effects of the great Indo-Asian haze. ACTA ACUST UNITED AC 2001. [DOI: 10.1029/2001jd900133] [Citation(s) in RCA: 1054] [Impact Index Per Article: 45.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
17
|
Cantrell W. Office automation: value for the hospital. South Hosp 1984; 52:26, 28, 30. [PMID: 10265573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
18
|
|
19
|
|
20
|
Cantrell W, Elko EE, Moesch B. Parasitemia in rats inoculated with varying numbers of Plasmodium berghei. J Parasitol 1970; 56:1224-6. [PMID: 5504543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
|
21
|
Elko EE, Cantrell W. Nonspecific phagocytic activity in rats infected with Plasmodium berghei and treated with amodiaquine or chloroquine. Am J Trop Med Hyg 1970; 19:899-904. [PMID: 5493052 DOI: 10.4269/ajtmh.1970.19.899] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
|
22
|
|
23
|
|
24
|
|
25
|
Cantrell W, Jordan HB. Relative Susceptibility of Aedes Aegypti, Aedes Albopictus, Aedes Canadensis and Anopheles Quadrimaculatus to Plasmodium Gallinaceum. J Infect Dis 1949; 85:170-2. [DOI: 10.1093/infdis/85.2.170] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Cantrell W, Jordan HB. Changes in the Infectiousness of Gametocytes During the Course of Plasmodium Gallinaceum Infections. J Infect Dis 1946; 78:153-9. [DOI: 10.1093/infdis/78.2.153] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
27
|
Coulston F, Cantrell W, Huff CG. The Distribution and Localization of Sporozoites and Pre-Erythrocytic Stages in Infections with Plasmodium Gallinaceum. J Infect Dis 1945. [DOI: 10.1093/infdis/76.3.226] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
|
29
|
Cantrell W, Webb W, Milligan W, Harvey G. A Query as to Registration. West J Med 1870. [DOI: 10.1136/bmj.2.518.618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
30
|
Cantrell W. THE PAY OF PARISH SURGEONS. West J Med 1855. [DOI: 10.1136/bmj.s3-3.154.1117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
31
|
Cantrell W. POOR-LAW GUARDIANS' READING OF THE VACCINATION ACT. West J Med 1855. [DOI: 10.1136/bmj.s3-3.152.1079-b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
32
|
Cantrell W. Conduct of the Poor-Law Authorities: Refusal of the Fee for Reducing a Dislocation. West J Med 1846. [DOI: 10.1136/bmj.s1-10.33.391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|